3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Virus Diseases
1
Tumor Virus Infections
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
Cyclophosphamide
4
Gemcitabine
3
isatuximab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Rituximab
2
Lenalidomide
2
Dexamethasone
2
Cisplatin
2
trametinib
1
spartalizumab
1
pomalidomide
1
pertuzumab
1
penpulimab
1
pembrolizumab
1
olaparib
1
niraparib
1
lutetium Lu 177 dotatate
1
ibritumomab tiuxetan
1
fludarabine
1
dabrafenib
1
copper dotatate CU-64
1
Trastuzumab
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Histologic Type
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled